Companies: 10,795·Total market cap: $144.5T
Verve Therapeutics, Inc.

Verve Therapeutics, Inc.

VERVNASDAQHealthcare
$11.13
+$0.03(+0.27%)
Market Cap$994044786
P/E Ratio—
52W High$11.405
52W Low$2.865
SEC Filings

Verve Therapeutics, Inc. (VERV) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001840574 · VERV · NASDAQ · as of Jun 8, 2026

Filing snapshot

344
Total Filings
SCHEDULE 13G
Latest Form
2025-08-14
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001840574 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-02-27
Fiscal Year End
Feb 27, 2025
Accession No.
0000950170-25-028376
Primary Document
verv-20241231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001840574 · Accession 0000950170-25-028376

Latest Key Filings

10-QQuarterly Report
10-Q
2025-05-14
View 10-Q on SEC
8-KCurrent Report
8-K
2025-07-25Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2025-08-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-08-14
View
15-12G15-12G
15-12G
2025-08-04
View
EFFECTEFFECT
EFFECT
2025-07-28
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-07-28
View
POS AMPOS AM
POS AM
2025-07-25
View
8-KCurrent Report
8-K
2025-07-25
View
POSASRPOSASR
POSASR
2025-07-25
View
S-8 POSS-8 POS
S-8 POS
2025-07-25
View
S-8 POSS-8 POS
S-8 POS
2025-07-25
View
S-8 POSS-8 POS
S-8 POS
2025-07-25
View
S-8 POSS-8 POS
S-8 POS
2025-07-25
View
S-8 POSS-8 POS
S-8 POS
2025-07-25
View
25-NSE25-NSE
25-NSE
2025-07-25
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2025-07-24
View
Showing 1–15 of 207 filingsForm 4 / 144 hidden· 344 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001840574  |  Exchange: NASDAQ · Healthcare

Verve Therapeutics, Inc. (NASDAQ: VERV) has submitted 344 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001840574, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Verve Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Verve Therapeutics, Inc. 10-K was filed on 2025-02-27 for fiscal year ending 2025. Historical VERV 10-K annual reports are available from 2021 through 2025.

Investors researching Verve Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
EQRX SEC Filings →VECT SEC Filings →PSTX SEC Filings →ALBO SEC Filings →HARP SEC Filings →CDMO SEC Filings →CBIO SEC Filings →ETHZ SEC Filings →
→ VERV Financials→ VERV Earnings→ VERV Insider Trades

Frequently Asked Questions

VERV SEC Filings · 8 questions

Verve Therapeutics, Inc. (VERV) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 344 filings and access original documents at no cost. Verve Therapeutics, Inc.'s CIK is 0001840574.

VERV SEC filingsVerve Therapeutics, Inc. SEC documentsfind VERV 10-K